{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:08:06Z","timestamp":1792098486705,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ijantimicag.2018.10.010","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T03:11:22Z","timestamp":1540523482000},"page":"152-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-4260","authenticated-orcid":false,"given":"Gregory Saraiva","family":"Medeiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-2613","authenticated-orcid":false,"given":"Maria Helena","family":"Rigatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-3833","authenticated-orcid":false,"given":"Diego Rodrigues","family":"Falci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre P.","family":"Zavascki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0001","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0002","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1473-3099(09)70054-4","article-title":"The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria","volume":"9","author":"Nordmann","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1469-0691.2011.03478.x","article-title":"Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections","volume":"18","author":"Ben-David","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cmi.2017.08.030","article-title":"Management of KPC-producing Klebsiella pneumoniae infections","volume":"24","author":"Bassetti","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0006","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0007","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.cmi.2015.08.001","article-title":"Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case\u2013control\u2013control study","volume":"21","author":"Giacobbe","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0008","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Gutierrez-Gutierrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0009","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0011","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.02634-15","article-title":"Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B","volume":"60","author":"Rigatto","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02319-16","article-title":"Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?","volume":"61","author":"Zavascki","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0013","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.03007-15","article-title":"Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"60","author":"Gomez-Simmonds","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0014","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.diagmicrobio.2010.02.001","article-title":"Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes","volume":"67","author":"Nguyen","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365548.2013.844350","article-title":"Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy","volume":"46","author":"Crusio","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0016","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. CLSI document M100-S25","year":"2015"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0017","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, 2017","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0018","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/jac\/dkr563","article-title":"Rapid detection of carbapenemase genes by multiplex real-time PCR","volume":"67","author":"Monteiro","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/SHK.0b013e318182f98f","article-title":"Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems","volume":"31","author":"Rhee","year":"2009","journal-title":"Shock"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0021","series-title":"CDC\/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the acute care setting","year":"2014"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0022","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cmi.2016.01.016","article-title":"Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"22","author":"Falcone","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0023","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","article-title":"Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment","volume":"17","author":"Zarkotou","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0024","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0034-1398390","article-title":"Colistin: how should it be dosed for the critically ill?","volume":"36","author":"Landersdorfer","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0025","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0026","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"The combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0027","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0028","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0029","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1586\/14787210.2013.845523","article-title":"Combination therapy for carbapenem-resistant Gram-negative bacteria","volume":"11","author":"Zavascki","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","article-title":"Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility","volume":"15","author":"Zavascki","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0032","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10096-014-2070-6","article-title":"Comparison of colistin\u2013carbapenem, colistin\u2013sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections","volume":"33","author":"Batirel","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.010_bib0033","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1086\/657135","article-title":"Bloodstream infections caused by metallo-\u03b2-lactamase\/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes","volume":"31","author":"Mouloudi","year":"2010","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:32:45Z","timestamp":1760376765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0924857918303029"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}